Introduction
Nitrous oxide (N 2 O) has been a mainstay of general anesthesia for over 160 years. First synthesized by Priestley in 1772, its psychotropic effects were first appreciated by Humphrey Davy in 1799. He encouraged its recreational use, but recommended it as an anesthetic for minor surgery. This call was not taken up until Horace Wells first used it for analgesia in 1844. As a colorless and odorless gas, nitrous oxide is acceptable to pediatric patients, making smooth mask inductions possible. Fast onset and quick resolution add to its attractive features. Although its low potency and ability to expand closed airspaces have long been known to present certain problems in specific clinical scenarios, from 1844 until 1956, despite widespread use, nitrous oxide was thought to be a completely safe agent. Beginning in 1956, reports of hematologic and neurologic complications first with repeated recreational exposure, and then with even limited clinical reexposure, have led clinicians and scientists to evaluate the biochemical effects of nitrous oxide. Although originally suspected to apply to only a small number of children with specific types of metabolic inborn errors, it has become apparent that these metabolic abnormalities may be present in a far larger number of individuals. In addition to these metabolic effects, the past several years have seen advances that have called into question the safety of routine nitrous oxide not only in the immature brain but also in that of the adult. In fact, the effect of nitrous oxide, and other volatile anesthetics, on the developing infant brain has become perhaps the most contentious area of current pediatric anesthesia discussion. In this review, we will discuss metabolic concerns of nitrous oxide use, followed by current concepts of the effects of nitrous oxide in the developing (and adult) brain, followed by recent information on the use of nitrous oxide in major (adult) surgery.
Metabolic concerns
Beginning in 1956, several reports appeared implicating nitrous oxide in the development of aplastic anemia or neurologic findings similar to those of megaloblastic anemia and B 12 deficiency. These individuals had prolonged or repeated exposures to nitrous oxide from clinical use [1, 2] or recreational use [3] [4] [5] . Brodsky et al. [6] also showed that there was an occupational hazard in dentists and dental assistants.
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by the enzyme methionine synthetase to S-adenosylmethionine, which is involved in many biologic reactions ( Fig. 1 ).This pathway iscrucial toDNAsynthesis andrepair pathways. Children with deficiencies of the enzyme methionine synthetase display megaloblastic changes, growth retardation, psychomotor retardation, neurologic problems, elevated homocysteine and diminished levels of methionine [7 ] . It has been shown that nitrous oxide inhibits methionine synthetase by 50% in rats after a 4-h exposure but recovery is complete by 2-4 days later [8] . Culley et al. [9 ] recently showed in late middle-aged rats that memory was persistently impaired after even a brief exposure to nitrous oxide at below minimal anesthetic concentration. Methionine synthetase activity was transiently depressed. Whether this deactivation of methionine synthetase is as severe in humans or if there is added insult to those with an innate methionine synthetase deficiency is unknown. The effectof depressionof related B 12 pathwaysbynitrousoxide in patients with methionine synthetase deficiency is unknown. It would seem reasonable to avoid nitrous oxide in children with methionine synthetase deficiency.
Also of concern is the use of nitrous oxide in patients with other defects in the metabolism of B 12 . Homocystinuria, the second most common disease of amino acid metabolism, can be a result of three different types of defects ( Fig. 1) . Type III is caused by a defect in 5,10-methylenetetrahydrofolate reductase (MTHFR) and, while an uncommon disease, fatal outcome has been reported with exposure to nitrous oxide [10] . A 3-month-old infant died after two exposures to nitrous oxide within 4 days. Neurologic signs (seizures and apnea) did not develop until postoperative day 25, with death on day 46. It was assumed that the combination of the genetic defect in MTHFR and the nitrous oxide-induced inhibition of methionine synthetase was fatal.
Although homocystinuria is an uncommon disorder, single nucleotide polymorphisms (SNPs) in MTHFR are common. Lacassie et al. [11] reported a patient with a MTHFR SNP (C ! T 677 ) who developed folate and B 12 responsive macrocytic anemia and a myelopathy after two exposures to nitrous oxide within 10 weeks. Twelve to 57% of the population is heterozygous for this SNP.
There is also a theoretical risk of nitrous oxide worsening findings in patients with methylmalonic acidemia, for which B 12 is a cofactor [12] . It has been shown, however, in rats that that this B 12 -dependent enzyme is unaffected by nitrous oxide, so the situation in humans is unclear [13] . Further discussion of nitrous oxide and these metabolic disorders can be found in a recent review [7 ] .
B 12 deficiency represents another category of patients at risk of a significant metabolic effect of nitrous oxide exposure. B 12 deficiency can result secondary to resection of the terminal ileum, pernicious anemia, or dietary restrictions, most commonly vegan, although it is also possible with protein restrictive diets such as those prescribed for phenylketonuria [14] . Case reports illustrate that B 12 -deficient patients exhibit neurologic and hematologic consequences after as little as 80 min of exposure to nitrous oxide and, as in the above case, the onset of findings can be delayed for weeks [15] [16] [17] . Of note to pediatric anesthesiologists, there have been two reports of breast-fed infants who developed anemia and/or neuropathy. The mothers of
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Hatched bars, points of nitrous oxide inhibition; MTHFR, methylene tetrahydrofolate reductase; Roman numerals refer to the three types of homocystinuria. Reprinted with permission from [7 ] .
both of these infants were B 12 deficient, from deficiency of intrinsic factor [15] or from a vegan diet [16] .
Nitrous oxide and brain development
Brain development is of key interest to the pediatric anesthesiologist. Recent studies have looked at the impact of anesthetics on the developing brain. Brain development in the human continues rapidly after birth during the period of synaptogenesis, which continues for several years. It is at this time that neurons rearrange in the brain to develop their synaptic connections. It is also during this time that some unnecessary neurons undergo apoptosis. Concern has been raised that anesthetics may accelerate apoptosis leading to neurotoxicity [18] .
Nitrous oxide is an N-methyl-D-aspartate (NMDA) receptor antagonist [19] . Rat models have been extensively used to examine the effects of anesthetics on the brain. It was found that low doses of nitrous oxide or ketamine, another NMDA antagonist, caused reversible damage to the adult rat brain, but that higher doses or repeated exposure caused irreversible damage [18] . An earlier study examined the effect of a common pediatric combination of anesthetics -midazolam, isoflurane and nitrous oxide on the young rat (7 days old) for 6 h. It was found that this combination caused widespread apoptotic neurodegeneration as well as memory and learning impairment [20] . Interestingly, in this study, when used alone, nitrous oxide produced no increase in apoptosis. It is difficult to examine the impact of these studies on the human brain and development. In rats, synaptogenesis spans from approximately 2 days before birth to about 2 weeks of age. In humans it begins during the last trimester and continues through the first few years of age. In the rat a 7-day-old correlates to a 1-6 month old human, and the 6-h anesthetic model would more closely represent long-term sedation in an intensive care unit than the durations of exposure in a surgical procedure [18] .
Slikker et al. [21 ] recently studied the impact of the NMDA antagonist ketamine in a primate model. In this study, late gestation and 5-day-old and 35-day-old rhesus monkeys were exposed to anesthetic doses of ketamine for 24 h (all groups) or 3 h (5-day-old infants only) . There was evidence of apoptotic and necrotic neuronal cell death in the prenatal and 5-day-old animals, but not in the 35-day-old animals. Of note to pediatric anesthesiologists, there was no neuronal cell death after a 3-h exposure in the 5-day-old neonates. Whether these findings would also be noted with the use of nitrous oxide has not yet been studied, but in rat models both ketamine and nitrous oxide result in similar types of cell death [18] .
Xenon, another NMDA antagonist and potent anesthetic, does not appear to cause apoptosis in rats [22 ] . In this study, young rats were exposed to one of eight gas mixtures of nitrous oxide, xenon and isoflurane alone or in combinations for 6 h. Isoflurane alone increased the rate of apoptosis, but neither nitrous oxide nor xenon alone caused accelerated cell death. The combination of nitrous oxide and isoflurane significantly increased, however, neuronal cell death above that seen with isoflurane alone. Interestingly, the combination of xenon and isoflurane did not increase the rate of apoptosis [22 ] .
Could nitrous oxide alone be a well tolerated method of sedation? As illustrated in at least two rodent models, nitrous oxide alone does not seem to be harmful to the developing brain [20, 22 ] . This is clearly an area that requires further study.
While we have focused on the implications of nitrous oxide use, nitrous oxide is not the only anesthetic with the potential to cause neurolgic damage. A review by Mellon et al. [23] analyzed the animal studies that have shown that many of the anesthetics in current practice cause neurodegeneration in animal studies. This review highlighted not only NMDA antagonists but also g-aminobutyric acid (GABA) agonists, and confirmed the current lack of human outcome data. It is important to recognize that additional research in the area of brain development is needed.
Nitrous oxide in major surgery
The use of nitrous oxide has also been associated with undesirable outcomes such as nausea and vomiting [24] . While seemingly a benign complication, nausea has considerable effects on patient satisfaction and on discharge times from ambulatory facilities.
A study by Myles et al. [25 ] recently compared the use of nitrous oxide with high-concentration oxygen during major surgery. The primary endpoint was the effect on hospital length of stay. Secondary endpoints included duration of intensive care stay, severe nausea and vomiting, pneumonia, pneumothorax, pulmonary embolism, wound infection, myocardial infarction, venous thromboembolism, stroke, awareness and death within 30 days of surgery. The study enrolled 2050 patients who were randomly assigned to receive a 70% nitrous oxide-based anesthesia or a nitrous oxide-free mixture that could include a range of oxygen concentrations from 25 to 100%. There was no difference in the primary endpoint of hospital stay between the two groups, but there were fewer major complications reported in the nitrous oxidefree group including a lower incidence of severe nausea or vomiting, fever, wound infection, pneumonia and atelectasis. This paper is open to some criticism, as the oxygen concentration was not controlled: the results could conceivably have been due to a higher FiO 2 in the non-nitrous oxide group. The oxygen concentration has been studied [26] by others to determine whether a higher concentration has beneficial effects. To further examine this factor Myles et al. [25 ] analyzed the nitrous oxide-free group to determine whether varying oxygen concentration had an effect on outcomes. While few of the patients received less than 51% oxygen, there was no discernable difference in outcomes between the patients who received high concentrations or low concentrations of oxygen.
High oxygen concentration is frequently undesirable in pediatric anesthesia. Supplemental oxygen may be beneficial to adults, but poses serious risks to premature infants. Neonates lack a mature antioxidant system and are unable to eliminate reactive oxygen species, which can lead to DNA damage [27] . Neonates are also at risk of developing retinopathy of prematurity and bronchopulmonary dysplasia with the administration of high inspired oxygen concentration [27, 28] . Beginning in 2005, the American Heart Association neonatal resuscitation guidelines called for the use of room air for newborns in distress [29] . This makes the Myles study very interesting but not necessarily fully applicable to very young pediatric patients.
Conclusion
Nitrous oxide is an anesthetic that has been used for many years without apparent ill effects on thousands of children and adults. However, new evidence in animal studies demonstrates that nitrous oxide may be deleterious to brain development and may be a potential risk to some of our most vulnerable premature and young infant patients. Nitrous oxide is also currently being studied in adults as a risk factor for increased adverse effects during major surgery. Although there is not enough evidence in humans to eliminate nitrous oxide from anesthetic practice, its use must be carefully considered for each patient.
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